Andrew Farquharson - 03 Feb 2022 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Director
Signature
/s/ Josh Seidenfeld, Attorney-in-Fact for Andrew Farquharson
Issuer symbol
RANI
Transactions as of
03 Feb 2022
Net transactions value
$0
Form type
4
Filing time
07 Feb 2022, 20:41:18 UTC
Previous filing
02 Aug 2021
Next filing
10 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RANI Class A Common Stock Other $0 -827,467 -100% $0.000000* 0 03 Feb 2022 See footnote F1, F2
transaction RANI Class A Common Stock Other $0 +66,127 $0.000000 66,127 03 Feb 2022 See footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration.
F2 Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP.
F3 InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4 VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.